Overview

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and clinical pharmacology of XOMA 358 in patients with hypoglycemia after gastric bypass surgery.
Phase:
Phase 2
Details
Lead Sponsor:
XOMA (US) LLC
Treatments:
Antibodies, Monoclonal